Drugs / Convacell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05726084 | Oct 2022 → Oct 2023 | COVID-19, respiratory tract infectious disorder | St. Petersburg Research Institute of Vaccines and Sera | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Convacell | “The goal of this clinical trial is to assess the immunogenicity, efficacy and safety of the Convacell vaccine in healthy adult volunteers aged 18 years and older.” NCT05726084 ↗ |
| Modality | Vaccine | “Convacell vaccine” NCT05726084 ↗ |